Top

Current Neurology and Neuroscience Reports

Published in:

18-03-2024 | Checkpoint Inhibitors | Review

Update on Neuro-ophthalmic Manifestations of Immune Checkpoint Inhibitors

Authors: Amalie Chen, Bart K. Chwalisz

Published in: Current Neurology and Neuroscience Reports | Issue 5/2024

Abstract

Purpose of Review

Immune checkpoint inhibitor (ICI) use has been on the rise for treatment of many different malignancies. Subsequently, more has been learned about immune-related adverse events (irAEs) that occur up to 12 months after treatment. This review summarizes the latest findings and management of neuro-ophthalmic associated irAEs.

Recent Findings

irAEs can affect the afferent and efferent neuro-ophthalmic pathways, thereby targeting central and peripheral nervous systems. As more cases are being reported, it is becoming apparent that neuro-ophthalmic irAEs often present with atypical features when compared to their spontaneous autoimmune counterparts. These neuro-ophthalmic presentations can also be signs of a more extensive inflammatory process that spans other organ systems, such as myopathies, endocrinopathies, and paraneoplastic syndromes.

Summary

Awareness of neuro-ophthalmic irAEs and their atypical presentations can lead to early detection, termination of ICI treatment, and immunosuppressant therapy initiation.

Lee JB, Kim HR, Ha SJ. Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy. Immune Network. 2022;22(1). https://doi.org/10.4110/in.2022.22.e2

• Guidon AC, Burton LB, Chwalisz BK, et al. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2021;9(7):e002890. https://doi.org/10.1136/jitc-2021-002890. These authors defined neurologic irAEs via consensus amongst a multi-disciplinary panel of neurologic and oncologic providers across 15 academic centers.CrossRefPubMedPubMedCentral

Farina A, Birzu C, Elsensohn MH, et al. Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity. Brain Commun. 2023;5(3):fcad169. https://doi.org/10.1093/braincomms/fcad169.CrossRefPubMedPubMedCentral

Winges KM, Gordon LK. Neuro-ophthalmic complications of immune checkpoint inhibitor therapy: current status and future directions. Front Ophthalmology. 2022;2. Accessed August 9, 2023. https://doi.org/10.3389/fopht.2022.1044904

Martens A, Schauwvlieghe PP, Madoe A, Casteels I, Aspeslagh S. Ocular adverse events associated with immune checkpoint inhibitors, a scoping review. J Ophthalmic Inflamm Infect. 2023;13(1):5. https://doi.org/10.1186/s12348-022-00321-2.CrossRefPubMedPubMedCentral

• Yu CW, Yau M, Mezey N, Joarder I, Micieli JA. Neuro-ophthalmic complications of immune checkpoint inhibitors: a systematic review. EB. 2020;12:139–67. https://doi.org/10.2147/EB.S277760. This paper summarizes the incidences of neuro-ophthalmic irAEs and their outcomes.CrossRef

Dine J, Gordon R, Shames Y, Kasler MK, Barton-Burke M. Immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer. Asia Pac J Oncol Nurs. 2017;4(2):127–35. https://doi.org/10.4103/apjon.apjon_4_17.CrossRefPubMedPubMedCentral

Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS ONE. 2013;8(1):e53745. https://doi.org/10.1371/journal.pone.0053745.CrossRefPubMedPubMedCentral

Sengul Samanci N, Ozan T, Çelik E, Demirelli FH. Optic neuritis related to atezolizumab treatment in a patient with metastatic non-small-cell lung cancer. JCO Oncol Pract. 2020;16(2):96–8. https://doi.org/10.1200/JOP.19.00438.CrossRef

10.

Thakolwiboon S, Karukote A, Wilms H. De novo myasthenia gravis induced by atezolizumab in a patient with urothelial carcinoma. Cureus. 11(6):e5002. https://doi.org/10.7759/cureus.5002

11.

Khoo A, Zhuang Y, Boundy K, Frasca J. Immune checkpoint inhibitor-related myositis associated with atezolizumab therapy. Neurol Clin Pract. 2019;9(3):e25–6. https://doi.org/10.1212/CPJ.0000000000000597.CrossRefPubMedPubMedCentral

12.

Noble CW, Gangaputra SS, Thompson IA, et al. Ocular adverse events following use of immune checkpoint inhibitors for metastatic malignancies. Ocul Immunol Inflamm. 2020;28(6):854–9. https://doi.org/10.1080/09273948.2019.1583347.CrossRefPubMed

13.

• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol. 2022;40(2):127–37. https://doi.org/10.1200/JCO.21.02229. The authors surveyed neuro-ophthalmologist members of North American Neuro-Ophthalmology Society (NANOS) to summarize the cases they observed and/or treated firsthand.CrossRefPubMed

14.

Pelcovits A, Mistry H, Chudasama R, Andrea S, Khurshid H. Risk factors for immune mediated adverse events with immune checkpoint inhibitors. JCO. 2021;39(15_suppl):2622–2622. https://doi.org/10.1200/JCO.2021.39.15_suppl.2622.CrossRef

15.

Chennamadhavuni A, Abushahin L, Jin N, Presley CJ, Manne A. Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors. Front Immunol. 2022;13:779691. https://doi.org/10.3389/fimmu.2022.779691.CrossRefPubMedPubMedCentral

16.

Arnaud-Coffin P, Maillet D, Gan HK, et al. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. Int J Cancer. 2019;145(3):639–48. https://doi.org/10.1002/ijc.32132.CrossRefPubMed

17.

Gu L, Khadaroo PA, Su H, et al. The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis. BMC Cancer. 2019;19:559. https://doi.org/10.1186/s12885-019-5785-z.CrossRefPubMedPubMedCentral

18.

Sun MM, Seleme N, Chen JJ, et al. Neuro-ophthalmic complications in patients treated with CTLA-4 and PD-1/PD-L1 checkpoint blockade. J Neuroophthalmol. 2021;41(4):519. https://doi.org/10.1097/WNO.0000000000001148.CrossRefPubMed

19.

Francis JH, Jaben K, Santomasso BD, et al. Immune checkpoint inhibitor associated optic neuritis. Ophthalmology. 2020;127(11):1585–9. https://doi.org/10.1016/j.ophtha.2020.05.003.CrossRefPubMed

20.

Takada K, Fujiwara K, Ando E, et al. Optic perineuritis associated with nivolumab treatment for non-small cell lung cancer. Case Rep Oncol. 2021;14(2):792–6. https://doi.org/10.1159/000516275.CrossRefPubMedPubMedCentral

21.

Kao JC, Liao B, Markovic SN, et al. Neurological complications associated with anti–programmed death 1 (PD-1) antibodies. JAMA Neurol. 2017;74(10):1216–22. https://doi.org/10.1001/jamaneurol.2017.1912.CrossRefPubMedPubMedCentral

22.

Hahn L, Pepple KL. Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma. J Ophthalmic Inflamm Infect. 2016;6(1):14. https://doi.org/10.1186/s12348-016-0082-3.CrossRefPubMedPubMedCentral

23.

Khimani K, Patel SP, Whyte A, Al-Zubidi N. Case report: neuromyelitis optica after treatment of uveal melanoma with nivolumab and ipilimumab. Front Oncol. 2022;12:806501. https://doi.org/10.3389/fonc.2022.806501.CrossRefPubMedPubMedCentral

24.

Narumi Y, Yoshida R, Minami Y, et al. Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report. BMC Cancer. 2018;18(1):95. https://doi.org/10.1186/s12885-018-3997-2.CrossRefPubMedPubMedCentral

25.

Shimada T, Hoshino Y, Tsunemi T, et al. Neuromyelitis optica spectrum disorder after treatment with pembrolizumab. Mult Scler Relat Disord. 2020;37:101447. https://doi.org/10.1016/j.msard.2019.101447.CrossRefPubMed

26.

Daetwyler E, Zippelius A, Meyer P, Läubli H. Pembrolizumab-induced optic neuropathy – a case report. Front Immunol. 2023;14:1171981. https://doi.org/10.3389/fimmu.2023.1171981.CrossRefPubMedPubMedCentral

27.

Goldstein BL, Gedmintas L, Todd DJ. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of CTLA-4. Arthritis Rheumatol. 2014;66(3):768–9. https://doi.org/10.1002/art.38282.CrossRefPubMed

28.

Micaily I, Chernoff M. An unknown reaction to pembrolizumab: giant cell arteritis. Ann Oncol. 2017;28(10):2621–2. https://doi.org/10.1093/annonc/mdx306.CrossRefPubMed

29.

Narala R, Reddy SA, Mruthyunjaya P. Giant cell arteritis manifesting as retinal arterial occlusion and paracentral acute middle maculopathy in a patient on pembrolizumab for metastatic uveal melanoma. Am J Ophthalmol Case Rep. 2020;20:100891. https://doi.org/10.1016/j.ajoc.2020.100891.CrossRefPubMedPubMedCentral

30.

Phase II clinical trial to assess the safety and efficacy of tocilizumab in combination with ipilimumab and nivolumab for treatment-naïve metastatic melanoma. ACR Meeting Abstracts. Accessed 28 Dec 2023. https://acrabstracts.org/abstract/phase-ii-clinical-trial-to-assess-the-safety-and-efficacy-of-tocilizumab-in-combination-with-ipilimumab-and-nivolumab-for-treatment-naive-metastatic-melanoma/.

31.

Campochiaro C, Farina N, Tomelleri A, et al. Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. Eur J Intern Med. 2021;93:87–94. https://doi.org/10.1016/j.ejim.2021.07.016.CrossRefPubMed

32.

Verheijden RJ, van Eijs MJM, May AM, van Wijk F, Suijkerbuijk KPM. Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance. npj Precis Onc. 2023;7(1):1–11. https://doi.org/10.1038/s41698-023-00380-1.CrossRef

33.

Kim D. Posterior reversible encephalopathy syndrome induced by nivolumab immunotherapy for non–small-cell lung cancer. Clin Case Rep. 2019;7(5):935–8. https://doi.org/10.1002/ccr3.2122.CrossRefPubMedPubMedCentral

34.

Duong SL, Prüss H. Paraneoplastic autoimmune neurological syndromes and the role of immune checkpoint inhibitors. Neurotherapeutics. 2022;19(3):848–63. https://doi.org/10.1007/s13311-022-01184-0.CrossRefPubMedPubMedCentral

35.

Yshii LM, Gebauer CM, Pignolet B, et al. CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model. Brain. 2016;139(11):2923–34. https://doi.org/10.1093/brain/aww225.CrossRefPubMed

36.

Maller B, Peguero E, Tanvetyanon T. Ipilimumab/nivolumab-related opsoclonus-myoclonus-ataxia syndrome variant in a patient with malignant pleural mesothelioma. J Immunother. 2018;41(9):411. https://doi.org/10.1097/CJI.0000000000000228.CrossRefPubMed

37.

Arai H, Utsu Y, Horio J, Furukawa S, Kikkawa Y. Paraneoplastic opsoclonus-myoclonus syndrome with anti-Hu and anti-SOX-1 antibodies after immune-checkpoint inhibitor treatment combined with chemotherapy in a patient with small-cell lung cancer. Intern Med. 2022;61(1):71–4. https://doi.org/10.2169/internalmedicine.7167-21.CrossRefPubMedPubMedCentral

38.

Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017;89(11):1127–34. https://doi.org/10.1212/WNL.0000000000004359.CrossRefPubMed

39.

Safa H, Johnson DH, Trinh VA, et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019;7(1):319. https://doi.org/10.1186/s40425-019-0774-y.CrossRefPubMedPubMedCentral

40.

Takamatsu K, Nakane S, Suzuki S, et al. Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia. Ann Clin Transl Neurol. 2018;5(11):1421–7. https://doi.org/10.1002/acn3.654.CrossRefPubMedPubMedCentral

41.

Johnson DB, Manouchehri A, Haugh AM, et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. 2019;7(1):134. https://doi.org/10.1186/s40425-019-0617-x.CrossRefPubMedPubMedCentral

42.

Huang YT, Chen YP, Lin WC, Su WC, Sun YT. Immune checkpoint inhibitor-induced myasthenia gravis. Front Neurol. 2020;11:634. https://doi.org/10.3389/fneur.2020.00634.CrossRefPubMedPubMedCentral

43.

Reynolds KL, Guidon AC. Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature. Oncologist. 2019;24(4):435–43. https://doi.org/10.1634/theoncologist.2018-0359.CrossRefPubMed

44.

Seki M, Uruha A, Ohnuki Y, et al. Inflammatory myopathy associated with PD-1 inhibitors. J Autoimmun. 2019;100:105–13. https://doi.org/10.1016/j.jaut.2019.03.005.CrossRefPubMed

45.

Moreira A, Loquai C, Pföhler C, et al. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer. 2019;106:12–23. https://doi.org/10.1016/j.ejca.2018.09.033.CrossRefPubMed

46.

Liewluck T, Kao JC, Mauermann ML. PD-1 inhibitor-associated myopathies: emerging immune-mediated myopathies. J Immunother. 2018;41(4):208. https://doi.org/10.1097/CJI.0000000000000196.CrossRefPubMed

47.

McElnea E, NíMhéalóid Á, Moran S, Kelly R, Fulcher T. Thyroid-like ophthalmopathy in a euthyroid patient receiving ipilimumab. Orbit. 2014;33(6):424–7. https://doi.org/10.3109/01676830.2014.949792.CrossRefPubMed

48.

Sagiv O, Kandl TJ, Thakar SD, et al. Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor therapy in cancer patients. Ophthalmic Plast Reconstr Surg. 2019;35(1):50. https://doi.org/10.1097/IOP.0000000000001161.CrossRefPubMed

49.

Chera A, Stancu AL, Bucur O. Thyroid-related adverse events induced by immune checkpoint inhibitors. Front Endocrinol (Lausanne). 2022;13:1010279. https://doi.org/10.3389/fendo.2022.1010279.CrossRefPubMed

50.

Hassanzadeh B, DeSanto J, Kattah JC. Ipilimumab-induced adenohypophysitis and orbital apex syndrome: importance of early diagnosis and management. Neuro-Ophthalmology. 2018;42(3):176–81. https://doi.org/10.1080/01658107.2017.1368090.CrossRefPubMed

51.

Campredon P, Imbert P, Mouly C, Grunenwald S, Mazières J, Caron P. Severe inflammatory ophthalmopathy in a euthyroid patient during nivolumab treatment. Euro Thyroid J. 2018;7(2):84–7. https://doi.org/10.1159/000485742.CrossRef

52.

Papavasileiou E, Prasad S, Freitag SK, Sobrin L, Lobo AM. Ipilimumab-induced ocular and orbital inflammation–a case series and review of the literature. Ocul Immunol Inflamm. 2016;24(2):140–6. https://doi.org/10.3109/09273948.2014.1001858.CrossRefPubMed

53.

Di Dalmazi G, Ippolito S, Lupi I, Caturegli P. Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment. Expert Rev Endocrinol Metab. 2019;14(6):381–98. https://doi.org/10.1080/17446651.2019.1701434.CrossRefPubMedPubMedCentral

54.

Hartmann A, Paparoupa M, Volkmer BG, Rompel R, Wittig A, Schuppert F. Autoimmune hypophysitis secondary to therapy with immune checkpoint inhibitors: four cases describing the clinical heterogeneity of central endocrine dysfunction. J Oncol Pharm Pract. 2020;26(7):1774–9. https://doi.org/10.1177/1078155220910202.CrossRefPubMed

55.

Vogrig A, Muñiz-Castrillo S, Joubert B, et al. Cranial nerve disorders associated with immune checkpoint inhibitors. Neurology. 2021;96(6):e866–75. https://doi.org/10.1212/WNL.0000000000011340.CrossRefPubMed

56.

Mancone S, Lycan T, Ahmed T, et al. Severe neurologic complications of immune checkpoint inhibitors: a single-center review. J Neurol. 2018;265(7):1636–42. https://doi.org/10.1007/s00415-018-8890-z.CrossRefPubMed

57.

Baird-Gunning JJD, Weerasinghe D, Silsby M, et al. Miller Fisher syndrome associated with immunotherapy for metastatic melanoma. Neurohospitalist. 2018;8(4):191–3. https://doi.org/10.1177/1941874418778957.CrossRefPubMedPubMedCentral

58.

McNeill CJ, Fehmi J, Gladwin J, Price C. A rare case of Miller Fisher variant of Guillain-Barré syndrome (GBS) induced by a checkpoint inhibitor. BMJ Case Reports CP. 2019;12(8):e229443. https://doi.org/10.1136/bcr-2019-229443.CrossRef

59.

Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563–80. https://doi.org/10.1038/s41571-019-0218-0.CrossRefPubMed

60.

Siegel CH, Finn RS, Ho MG. Multiple cranial neuropathies from nivolumab in a patient with metastatic hepatocellular carcinoma. Mayo Clin Proc. 2018;93(4):540–1. https://doi.org/10.1016/j.mayocp.2018.01.001.CrossRefPubMed

61.

Soror NN, Hemrock L, Shah P, et al. Brain stem encephalitis in a patient with recurrent small cell lung cancer treated with immune checkpoint inhibitor: case presentation and review of the literature. Cureus. 2021;13(1). https://doi.org/10.7759/cureus.13034

62.

Kawamura R, Nagata E, Mukai M, et al. Acute cerebellar ataxia induced by nivolumab. Intern Med. 2017;56(24):3357–9. https://doi.org/10.2169/internalmedicine.8895-17.CrossRefPubMedPubMedCentral

63.

Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. JCO. 2021;39(36):4073–126. https://doi.org/10.1200/JCO.21.01440.CrossRef

64.

Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆. Ann Oncol. 2022;33(12):1217–38. https://doi.org/10.1016/j.annonc.2022.10.001.CrossRefPubMed

65.

Poto R, Troiani T, Criscuolo G, et al. Holistic approach to immune checkpoint inhibitor-related adverse events. Front Immunol. 2022;13:804597. https://doi.org/10.3389/fimmu.2022.804597.CrossRefPubMedPubMedCentral

66.

Sechi E, Markovic SN, McKeon A, et al. Neurologic autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes. Neurology. 2020;95(17):e2442–52. https://doi.org/10.1212/WNL.0000000000010632.CrossRefPubMedPubMedCentral

Title: Update on Neuro-ophthalmic Manifestations of Immune Checkpoint Inhibitors
Authors: Amalie Chen
Bart K. Chwalisz
Publication date: 18-03-2024
Publisher: Springer US
Keywords: Checkpoint Inhibitors
Myasthenia Gravis
Optic Neuritis
Giant Cell Arteritis
Giant Cell Arteritis
Posterior Reversible Encephalopathy Syndrome
Paraneoplastic Syndromes
Myopathy
Published in: Current Neurology and Neuroscience Reports / Issue 5/2024
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-024-01336-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Update on Neuro-ophthalmic Manifestations of Immune Checkpoint Inhibitors

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content